SynthesisThoracic cancer2026
A Meta-Analysis on the Incidence and Associated Factors of Pulmonary Fungal Infections in Lung Cancer Patients: Evidence Predominantly From Chinese Studies in the Chinese and English Literature.
Synthesis in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incidence and risk factors of infections in lung cancer patients receiving immunotherapy combined with chemotherapy: a real-world retrospective study.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies report variation in the incidence of pulmonary fungal infection rates and associated factors in lung cancer patients. This meta-analysis aimed to provide a comprehensive synthesis of Chinese- and English-language studies to investigate the incidence of pulmonary fungal infections and their associated factors in these patients.
methodsStudies reporting the incidence of pulmonary fungal infections or their associated factors in lung cancer patients were systematically searched in the WanFang, CNKI, EMBASE, SinoMed, Web of Science, and PubMed databases until April 2025.
resultsIn total, 37 studies involving 26 841 lung cancer patients were included. The pooled pulmonary fungal infection rate (95% confidence interval) was 14.00% (12.54%-15.45%) in lung cancer patients. Age ≥ 60 years (odds ratio (OR) = 1.85, p = 0.020), male sex (OR = 1.23, p = 0.019), smoking history (OR = 2.24, p < 0.001), chronic obstructive pulmonary disease (OR = 2.19, p = 0.010), interstitial lung disease (OR = 4.40, p < 0.001), diabetes (OR = 2.31, p < 0.001), anemia (OR = 6.47, p = 0.016), small cell lung cancer (OR = 1.46, p = 0.011), squamous cell carcinoma (OR = 1.38, p = 0.001), tumor stages of III-IV (OR = 2.38, p < 0.001), invasive operation (OR = 3.73, p < 0.001), chemotherapy (OR = 1.64, p = 0.011), chemotherapy cycle > 2 (OR = 2.87, p < 0.001), radiotherapy (OR = 1.67, p = 0.001), chemoradiotherapy (OR = 2.72, p < 0.001), surgery (OR = 1.64, p < 0.001), long-term use of antibiotics (OR = 5.64, p = 0.002), use of glucocorticoid (OR = 4.44, p < 0.001), and hospital stays ≥ 14 days (OR = 3.97, p = 0.006) were linked with higher pulmonary fungal infection risk.
conclusionThe pulmonary fungal infection rate (95% CI) was 14.00% (12.54%, 15.45%) in lung cancer patients. Furthermore, the associated factors might help screen for and intervene early in pulmonary fungal infections in patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.